Anna Oleksiak: Is Thrombocytopenia in Critical Cardiac Care HIT?
Anna Oleksiak, Cardiologist at National Institute of Cardiology Stefan Cardinal Wyszyński – National Research Institute, shared a post on LinkedIn:
”At ICCU often patient’s platelets drop…
The clinical question – is this HIT, drugs interaction, mechanical injury, MCS, clotting, sepsis or something else?
But there is not much time for the right decisions.
Here are some pages from Association for Acute CardioVascular Care – ACVC Clinical Decision Making Toolkit, chapter about anticoagulation in critically ill, written by me and Christophe Vandenbriele last year.
Some hot points about heparin-induced thrombocytopenia:
- T Score is the most widely used and well-validated risk-prediction score and has excellent negative predictive value.
- An important problem in diagnosing thrombocytopenia is the exclusion of pseudothrombocytopenia, resulting from platelet agglutination in blood collected in an EDTA.
- HIT should be suspected in patients receiving heparin if, for an unknown reason:
1) the platelet count has decreased by ≥50% from the baseline (even if it is 150,000/µL);
2) ≥5 days have passed since the start of heparin administration;
3) a thromboembolic event has occurred;
4) no other causes of thrombocytopenia are identified.
- UFH conveys a HIT risk 10 times greater than that of LMWH.
- Frequently, post-surgical patients exhibit a unique bimodal pattern of platelet decline.
- Although thrombocytopenia is usually a serious problem in the context of bleeding, the occurrence of HIT type II is associated with a 20-40 fold increase in the risk of venous or arterial thrombosis, with an incidence of thrombosis ranging from 50% to 89% in untreated patients.
- The most common cause of death in patients with HIT is pulmonary embolism, less frequently stroke.
- Typically, the heparin-dependent antibodies fall to undetectable levels after 50 to 85 days.”

Stay updated with Hemostasis Today.
-
Aug 21, 2026, 15:53Gregory Lim: Nicotine Products and Cardiovascular Risk
-
Aug 21, 2026, 15:26Mariusz Kruk: Plaque-Directed Intervention for the Prevention of Myocardial Infarction
-
Aug 21, 2026, 15:17Leveraging Data to Drive Sustainable Care for Haemophilia and Haemoglobinopathies – NNHF
-
Aug 21, 2026, 15:04Sex Differences in Platelet Function in Type 2 Diabetes – Seminars in Thrombosis and Hemostasis
-
Aug 21, 2026, 15:04Parth Parmar: RBC Morphology – A Practical Guide to Blood Smear Interpretation
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis